Pyoderma gangrenosum.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
08 10 2020
08 10 2020
Historique:
accepted:
13
08
2020
entrez:
9
10
2020
pubmed:
10
10
2020
medline:
16
6
2021
Statut:
epublish
Résumé
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that presents with rapidly developing, painful skin ulcers hallmarked by undermined borders and peripheral erythema. Epidemiological studies indicate that the average age of PG onset is in the mid-40s, with an incidence of a few cases per million person-years. PG is often associated with a variety of other immune-mediated diseases, most commonly inflammatory bowel disease and rheumatoid arthritis. The cause of PG is not well understood, but PG is generally considered an autoinflammatory disorder. Studies have focused on the role of T cells, especially at the wound margin; these cells may support the destructive autoinflammatory response by the innate immune system. PG is difficult to diagnose as several differential diagnoses are possible; in addition to clinical examination, laboratory tests of biopsied wound tissue are required for an accurate diagnosis, and new validated diagnostic criteria will facilitate the process. Treatment of PG typically starts with fast-acting immunosuppressive drugs (corticosteroids and/or cyclosporine) to reduce inflammation followed by the addition of more slowly acting immunosuppressive drugs with superior adverse event profiles, including biologics (in particular, anti-tumour necrosis factor (TNF) agents). Appropriate wound care is also essential. Future research should focus on PG-specific outcome measures and PG quality-of-life studies.
Identifiants
pubmed: 33033263
doi: 10.1038/s41572-020-0213-x
pii: 10.1038/s41572-020-0213-x
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
81Subventions
Organisme : Wellcome Trust
ID : 205039/Z/16/Z
Pays : United Kingdom
Références
Wang, E. A. & Maverakis, E. The rapidly evolving lesions of ulcerative pyoderma gangrenosum: a timeline. Int. J. Dermatol. 57, 983–984 (2018). This is the first photographic documentation of the temporal evolution of a PG ulcer.
pubmed: 29806128
pmcid: 29806128
Hurwitz, R. M. & Haseman, J. H. The evolution of pyoderma gangrenosum. A clinicopathologic correlation. Am. J. Dermatopathol. 15, 28–33 (1993).
pubmed: 8434729
pmcid: 8434729
Brunsting, L. A., Goeckerman, W. H. & O’Leary, P. A. Pyoderma (echthyma) gangrenosum - clinical and experimental observations in five cases occurring in adults. Arch. Dermatol. Syphilol. 22, 655–680 (1930). This manuscript is the first well-documented description of PG, introducing concepts such as disease associations and ulcers occuring at sites of trauma.
Perry, H. O. & Brunsting, L. A. Pyoderma gangrenosum; a clinical study of nineteen cases. AMA Arch. Derm. 75, 380–386 (1957).
pubmed: 13402210
pmcid: 13402210
Brocq, L. & Simon, C. L. Contribution à l’étude du phagédénisme. Bull. Soc Med. Hôp. Paris 25, 290–307 (1908). Some experts consider this article to be the first report of PG.
Hobbs, M. M. & Ortega-Loayza, A. G. Pyoderma gangrenosum: from historical perspectives to emerging investigations. Int. Wound J. https://doi.org/10.1111/iwj.13389 (2020).
doi: 10.1111/iwj.13389
pubmed: 32378319
pmcid: 32378319
Patel, F. et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm. Venereol. 95, 525–531 (2015).
pubmed: 25387526
pmcid: 25387526
Borda, L. J., Wong, L. L., Marzano, A. V. & Ortega-Loayza, A. G. Extracutaneous involvement of pyoderma gangrenosum. Arch. Dermatol. Res. 311, 425–434 (2019).
pubmed: 30923901
pmcid: 30923901
Wallach, D. & Vignon-Pennamen, M. D. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J. Am. Acad. Dermatol. 55, 1066–1071 (2006).
pubmed: 17097401
pmcid: 17097401
Marzano, A. V., Borghi, A., Wallach, D. & Cugno, M. A comprehensive review of neutrophilic diseases. Clin. Rev. Allergy Immunol. 54, 114–130 (2018).
pubmed: 28688013
pmcid: 28688013
Marzano, A. V. et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin. Exp. Immunol. 162, 100–107 (2010).
pubmed: 20636397
pmcid: 20636397
Maverakis, E. et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 154, 461–466 (2018). This article establishes validated PG diagnostic criteria.
pubmed: 29450466
pmcid: 29450466
Kastner, D. L., Aksentijevich, I. & Goldbach-Mansky, R. Autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784–790 (2010).
pubmed: 20303869
pmcid: 20303869
Farasat, S., Aksentijevich, I. & Toro, J. R. Autoinflammatory diseases: clinical and genetic advances. Arch. Dermatol. 144, 392–402 (2008).
pubmed: 18347298
pmcid: 18347298
Satoh, T. K., Mellett, M., Contassot, E. & French, L. E. Are neutrophilic dermatoses autoinflammatory disorders? Br. J. Dermatol. 178, 603–613 (2018).
pubmed: 27905098
pmcid: 27905098
Cugno, M., Borghi, A. & Marzano, A. V. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am. J. Clin. Dermatol. 18, 555–562 (2017).
pubmed: 28236224
pmcid: 28236224
Marzano, A. V. et al. Mechanisms of inflammation in neutrophil-mediated skin diseases. Front. Immunol. 10, 1059 (2019).
pubmed: 31139187
pmcid: 31139187
Xu, A., Balgobind, A., Strunk, A., Garg, A. & Alloo, A. Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis. J. Am. Acad. Dermatol. https://doi.org/10.1016/j.jaad.2019.08.001 (2019).
doi: 10.1016/j.jaad.2019.08.001
pubmed: 31669080
pmcid: 31669080
Langan, S. M., Groves, R. W., Card, T. R. & Gulliford, M. C. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J. Invest. Dermatol. 132, 2166–2170 (2012). This is one of the largest studies on PG disease associations, mortality and incidence.
pubmed: 22534879
pmcid: 22534879
Monari, P. et al. Epidemiology of pyoderma gangrenosum: results from an Italian prospective multicentre study. Int. Wound J. 15, 875–879 (2018).
pubmed: 29877043
pmcid: 29877043
Vavricka, S. R. et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am. J. Gastroenterol. 106, 110–119 (2011).
pubmed: 20808297
pmcid: 20808297
Sharon, V. et al. Multimodal therapy of idiopathic pyoderma gangrenosum. Dermatol. Online J. 20, 6 (2014).
Bromeo, A. J. & Suller, A. Pyoderma gangrenosum of the upper eyelid. BMJ Case Rep. https://doi.org/10.1136/bcr-2019-230645 (2019).
doi: 10.1136/bcr-2019-230645
pubmed: 31874848
pmcid: 31874848
Kechichian, E. et al. Pediatric pyoderma gangrenosum: a systematic review and update. Int. J. Dermatol. 56, 486–495 (2017).
pubmed: 28233293
pmcid: 28233293
Schoch, J. J., Tolkachjov, S. N., Cappel, J. A., Gibson, L. E. & Davis, D. M. Pediatric pyoderma gangrenosum: a retrospective review of clinical features, etiologic associations, and treatment. Pediatr. Dermatol. 34, 39–45 (2017).
pubmed: 27699861
pmcid: 27699861
Gilman, A. L., Cohen, B. A., Urbach, A. H. & Blatt, J. Pyoderma gangrenosum as a manifestation of leukemia in childhood. Pediatrics 81, 846–848 (1988).
pubmed: 3285315
pmcid: 3285315
Paller, A. S., Sahn, E. E., Garen, P. D., Dobson, R. L. & Chadwick, E. G. Pyoderma gangrenosum in pediatric acquired immunodeficiency syndrome. J. Pediatr. 117, 63–66 (1990).
pubmed: 2370611
pmcid: 2370611
Hayani, A., Steuber, C. P., Mahoney, D. H. Jr. & Levy, M. L. Pyoderma gangrenosum in childhood leukemia. Pediatr. Dermatol. 7, 296–298 (1990).
pubmed: 2080124
pmcid: 2080124
Omidi, C. J. & Siegfried, E. C. Chronic recurrent multifocal osteomyelitis preceding pyoderma gangrenosum and occult ulcerative colitis in a pediatric patient. Pediatr. Dermatol. 15, 435–438 (1998).
pubmed: 9875964
pmcid: 9875964
Ashchyan, H. J. et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 154, 409–413 (2018).
pubmed: 29450453
pmcid: 29450453
Bennett, M. L. et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 79, 37–46 (2000). This retrospective study from two university-affiliated programmes distinguishes the differences between classic ulcerative PG and atypical PG in terms of the location of lesions and associated diseases.
pubmed: 10670408
pmcid: 10670408
Kolios, A. G. A. et al. Clinical disease patterns in a regional swiss cohort of 34 pyoderma gangrenosum patients. Dermatology 233, 268–276 (2017).
pubmed: 29130957
pmcid: 29130957
Al Ghazal, P. et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J. Rare Dis. 8, 136 (2013).
pubmed: 24010984
pmcid: 24010984
Kaffenberger, B. H., Hinton, A. & Krishna, S. G. The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: a national survey. J. Am. Acad. Dermatol. 79, 659–663 e652 (2018).
pubmed: 29438762
pmcid: 29438762
Sasor, S. E. et al. Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases. J. Wound Care 27, S4–S8 (2018).
pubmed: 29334018
pmcid: 29334018
Gupta, A. S. & Ortega-Loayza, A. G. Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. Ann. Hematol. 98, 2247–2248 (2019).
pubmed: 31230113
pmcid: 31230113
Kridin, K., Cohen, A. D. & Amber, K. T. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am. J. Clin. Dermatol. 19, 479–487 (2018).
pubmed: 29721816
pmcid: 29721816
Card, T. R., Langan, S. M. & Chu, T. P. Extra-gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported. Dig. Dis. Sci. 61, 2619–2626 (2016).
pubmed: 27193564
pmcid: 27193564
Henry, C. M. et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 14, 708–722 (2016).
pubmed: 26776523
pmcid: 26776523
Wang, E. A. et al. Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies. Front. Immunol. 8, 1980 (2017). This article proposes PG to be a T cell-mediated disease.
pubmed: 29379508
pmcid: 29379508
Takeuchi, F., Sterilein, R. D. & Hall, R. P. 3rd. Increased E-selectin, IL-8 and IL-10 gene expression in human skin after minimal trauma. Exp. Dermatol. 12, 777–783 (2003).
pubmed: 14714557
pmcid: 14714557
Maverakis, E., van den Elzen, P. & Sercarz, E. E. Self-reactive T cells and degeneracy of T cell recognition: evolving concepts-from sequence homology to shape mimicry and TCR flexibility. J. Autoimmun. 16, 201–209 (2001).
pubmed: 11334484
pmcid: 11334484
Marzano, A. V., Borghi, A., Meroni, P. L. & Cugno, M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br. J. Dermatol. 175, 882–891 (2016).
pubmed: 27106250
pmcid: 27106250
Nesterovitch, A. B. et al. Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am. J. Pathol. 178, 1434–1441 (2011).
pubmed: 21406173
pmcid: 21406173
Lorenz, U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol. Rev. 228, 342–359 (2009).
pubmed: 19290938
pmcid: 19290938
Zhang, J., Somani, A. K. & Siminovitch, K. A. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol. 12, 361–378 (2000).
pubmed: 10995583
pmcid: 10995583
Nesterovitch, A. B. et al. Spontaneous insertion of a B2 element in the Ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humans. Am. J. Pathol. 178, 1701–1714 (2011).
pubmed: 21435452
pmcid: 21435452
Nesterovitch, A. B. et al. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin. Exp. Dermatol. 36, 889–895 (2011).
pubmed: 21790734
pmcid: 21790734
Wise, C. A. et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 11, 961–969 (2002).
pubmed: 11971877
pmcid: 11971877
Smith, E. J. et al. Clinical, molecular, and genetic characteristics of PAPA syndrome: a review. Curr. Genomics 11, 519–527 (2010).
pubmed: 21532836
pmcid: 21532836
Dinarello, C. A. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur. J. Immunol. 41, 1203–1217 (2011).
pubmed: 21523780
pmcid: 21523780
Weiss, D. I. et al. IL-1beta induces the rapid secretion of the antimicrobial protein IL-26 from Th17 cells. J. Immunol. 203, 911–921 (2019).
pubmed: 31235553
pmcid: 31235553
Marzano, A. V. et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br. J. Dermatol. 176, 1588–1598 (2017).
pubmed: 27943240
pmcid: 27943240
Braun-Falco, M., Kovnerystyy, O., Lohse, P. & Ruzicka, T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)–a new autoinflammatory syndrome distinct from PAPA syndrome. J. Am. Acad. Dermatol. 66, 409–415 (2012).
pubmed: 21745697
pmcid: 21745697
Marzano, A. V., Ishak, R. S., Colombo, A., Caroli, F. & Crosti, C. Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome following bowel bypass surgery. Dermatology 225, 215–219 (2012).
pubmed: 23171584
pmcid: 23171584
Marzano, A. V. et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine 93, e187 (2014).
pubmed: 25501066
pmcid: 25501066
van der Zee, H. H. & Jemec, G. B. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J. Am. Acad. Dermatol. 73, S23–S26 (2015).
pubmed: 26470610
pmcid: 26470610
Tricarico, P. M. et al. An integrated approach to unravel hidradenitis suppurativa etiopathogenesis. Front. Immunol. 10, 892 (2019).
pubmed: 31105704
pmcid: 31105704
Ortega-Loayza, A. G. et al. Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum. Br. J. Dermatol. 178, e35–e36 (2018).
pubmed: 28734003
pmcid: 28734003
Nesterovitch, A. B., Arbieva, Z., Toth, D. M., Tharp, M. D. & Glant, T. T. A differential gene expression study: Ptpn6 (SHP-1)-insufficiency leads to neutrophilic dermatosis-like disease (NDLD) in mice. J. Dermatol. Sci. 83, 17–25 (2016).
pubmed: 27020408
pmcid: 27020408
Kolios, A. G. A. et al. Comparison of pyoderma gangrenosum and Martorell hypertensive ischaemic leg ulcer in a Swiss cohort. Br. J. Dermatol. 178, e125–e126 (2018).
pubmed: 28832960
pmcid: 28832960
Lukens, J. R. & Kanneganti, T. D. SHP-1 and IL-1alpha conspire to provoke neutrophilic dermatoses. Rare Dis. 2, e27742 (2014).
pubmed: 25054090
pmcid: 25054090
Lukens, J. R. et al. RIP1-driven autoinflammation targets IL-1alpha independently of inflammasomes and RIP3. Nature 498, 224–227 (2013). This article provides evidence for a potential unique role of IL-1α in autoinflammation.
pubmed: 23708968
pmcid: 23708968
Tartey, S., Gurung, P., Dasari, T. K., Burton, A. & Kanneganti, T. D. ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis. J. Clin. Invest. 128, 2042–2047 (2018).
pubmed: 29629899
pmcid: 29629899
Tartey, S., Gurung, P., Samir, P., Burton, A. & Kanneganti, T. D. Cutting edge: dysregulated CARD9 signaling in neutrophils drives inflammation in a mouse model of neutrophilic dermatoses. J. Immunol. 201, 1639–1644 (2018).
pubmed: 30082320
pmcid: 30082320
Marzano, A. V. et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin. Exp. Immunol. 178, 48–56 (2014).
pubmed: 24903614
pmcid: 24903614
Palanivel, J. A., Macbeth, A. E. & Levell, N. J. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation. Clin. Exp. Dermatol. 38, 44–46 (2013).
pubmed: 22607468
pmcid: 22607468
Guenova, E. et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch. Dermatol. 147, 1203–1205 (2011). This article provides evidence that IL-23 is central to PG pathophysiology.
pubmed: 21680759
pmcid: 21680759
Fletcher, J., Alhusayen, R. & Alavi, A. Recent advances in managing and understanding pyoderma gangrenosum. F1000Res https://doi.org/10.12688/f1000research.19909.1 (2019).
doi: 10.12688/f1000research.19909.1
pubmed: 31885859
pmcid: 31885859
Tanaka, N., Fujioka, A., Tajima, S., Ishibashi, A. & Hirose, S. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Brit J. Dermatol. 143, 728–732 (2000).
Johnston, A. et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 140, 109–120 (2017).
pubmed: 28043870
pmcid: 28043870
Carrier, Y. et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol. 131, 2428–2437 (2011).
pubmed: 21881584
pmcid: 21881584
Bamias, G., Corridoni, D., Pizarro, T. T. & Cominelli, F. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 59, 451–459 (2012).
pubmed: 22795953
pmcid: 22795953
Russell, S. E. et al. IL-36alpha expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunol. 9, 1193–1204 (2016).
pubmed: 26813344
pmcid: 26813344
Boutet, M. A. et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin. Exp. Immunol. 184, 159–173 (2016).
pubmed: 26701127
pmcid: 26701127
Hessam, S. et al. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br. J. Dermatol. 178, 761–767 (2018).
pubmed: 28975626
pmcid: 28975626
Senra, L. et al. IL-17E (IL-25) Enhances innate immune responses during skin inflammation. J. Invest. Dermatol. 139, 1732–1742.e1717 (2019).
pubmed: 30738055
pmcid: 30738055
Pappu, R., Ramirez-Carrozzi, V. & Sambandam, A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 134, 8–16 (2011).
pubmed: 21726218
pmcid: 21726218
Hvid, M. et al. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? J. Invest. Dermatol. 131, 150–157 (2011).
pubmed: 20861853
pmcid: 20861853
Xu, M. & Dong, C. IL-25 in allergic inflammation. Immunol. Rev. 278, 185–191 (2017).
pubmed: 28658555
pmcid: 28658555
Senra, L. et al. Keratinocyte-derived IL-17E contributes to inflammation in psoriasis. J. Invest. Dermatol. 136, 1970–1980 (2016).
pubmed: 27329229
pmcid: 27329229
Yeon, H. B., Lindor, N. M., Seidman, J. G. & Seidman, C. E. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am. J. Hum. Genet. 66, 1443–1448 (2000).
pubmed: 10729114
pmcid: 10729114
Oka, M. et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab. Invest. 80, 595–604 (2000).
pubmed: 10780675
pmcid: 10780675
Baggiolini, M., Dewald, B. & Moser, B. Interleukin-8 and related chemotactic cytokines–CXC and CC chemokines. Adv. Immunol. 55, 97–179 (1994).
pubmed: 8304236
pmcid: 8304236
Smith, S. et al. IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. JCI Insight https://doi.org/10.1172/jci.insight.120798 (2018).
doi: 10.1172/jci.insight.120798
pubmed: 30429369
pmcid: 30429369
Brooklyn, T. N. et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55, 505–509 (2006). This is the first randomized controlled trial in PG.
pubmed: 16188920
pmcid: 16188920
Matsushima, K. et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J. Exp. Med. 167, 1883–1893 (1988).
pubmed: 3260265
pmcid: 3260265
Maverakis, E. et al. Light, including ultraviolet. J. Autoimmun. 34, J247–J257 (2010).
pubmed: 20018479
pmcid: 20018479
Strieter, R. M. et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science 243, 1467–1469 (1989).
pubmed: 2648570
pmcid: 2648570
Xia, P. et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc. Natl Acad. Sci. USA 95, 14196–14201 (1998).
pubmed: 9826677
pmcid: 9826677
Sharma, D., Malik, A., Guy, C., Vogel, P. & Kanneganti, T. D. TNF/TNFR axis promotes pyrin inflammasome activation and distinctly modulates pyrin inflammasomopathy. J. Clin. Invest. 129, 150–162 (2019).
pubmed: 30457980
Su, W. P., Schroeter, A. L., Perry, H. O. & Powell, F. C. Histopathologic and immunopathologic study of pyoderma gangrenosum. J. Cutan. Pathol. 13, 323–330 (1986). This article is one of the first to note a predominance of peripheral lymphocytes in PG.
pubmed: 3537032
pmcid: 3537032
Brooklyn, T. N., Williams, A. M., Dunnill, M. G. & Probert, C. S. T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking. Br. J. Dermatol. 157, 960–966 (2007).
pubmed: 17935516
pmcid: 17935516
Foster, A. M. et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 192, 6053–6061 (2014).
pubmed: 24829417
pmcid: 24829417
Ackerman, A. B. An algorithmic method for histologic diagnosis of inflammatory and neoplastic skin diseases by analysis of their patterns. Am. J. Dermatopathol. 7, 105–107 (1985).
pubmed: 4025726
pmcid: 4025726
Abraham, C. & Cho, J. H. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066–2078 (2009).
pubmed: 19923578
pmcid: 19923578
Chen, W. T. & Chi, C. C. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. https://doi.org/10.1001/jamadermatol.2019.0891 (2019).
doi: 10.1001/jamadermatol.2019.0891
pubmed: 31339510
pmcid: 31339510
Billmeier, U., Dieterich, W., Neurath, M. F. & Atreya, R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J. Gastroenterol. 22, 9300–9313 (2016).
pubmed: 27895418
pmcid: 27895418
Antiga, E. et al. T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum. Clin. Exp. Immunol. 189, 383–391 (2017).
pubmed: 28518224
pmcid: 28518224
Caproni, M. et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br. J. Dermatol. 173, 275–278 (2015).
pubmed: 25601218
pmcid: 25601218
Gooderham, M. J., Papp, K. A. & Lynde, C. W. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J. Eur. Acad. Dermatol. Venereol. 32, 1111–1119 (2018).
pubmed: 29438576
pmcid: 29438576
Gaffen, S. L., Jain, R., Garg, A. V. & Cua, D. J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14, 585–600 (2014).
pubmed: 25145755
pmcid: 25145755
Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005).
pubmed: 15657292
pmcid: 15657292
McGeachy, M. J., Cua, D. J. & Gaffen, S. L. The IL-17 family of cytokines in health and disease. Immunity 50, 892–906 (2019).
pubmed: 30995505
pmcid: 30995505
Barnett, M. H. & Prineas, J. W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55, 458–468 (2004).
pubmed: 15048884
pmcid: 15048884
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M. & O’Garra, A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815–3822 (1991).
pubmed: 1940369
pmcid: 1940369
Horvath, R., Duffy, P. & McCormack, J. G. Necrotic ulceration of the skin and fascia. Clin. Infect. Dis. 36, 925–926 (2003).
Thomas, R. H. M., Payne, C. M. E. R. & Black, M. M. Wegener’s granulomatosis presenting as pyoderma gangrenosum. Clin. Exp. Dermatol. 7, 523–527 (1982).
pubmed: 7172488
pmcid: 7172488
Weenig, R. H., Davis, M. D. P., Dahl, P. R. & Su, W. P. D. Skin ulcers misdiagnosed as pyoderma gangrenosum. N. Engl. J. Med. 347, 1412–1418 (2002).
pubmed: 12409543
pmcid: 12409543
Duguid, C. M., O’Loughlin, S., Otridge, B. & Powell, F. C. Paraneoplastic pyoderma gangrenosum. Australas. J. Dermatol. 34, 17–22 (1993).
pubmed: 8240182
pmcid: 8240182
Maverakis, E., Goodarzi, H., Wehrli, L. N., Ono, Y. & Garcia, M. S. The etiology of paraneoplastic autoimmunity. Clin. Rev. Allergy Immunol. 42, 135–144 (2012).
pubmed: 21246308
pmcid: 21246308
Montagnon, C. M. et al. Pyoderma gangrenosum in hematologic malignancies: a systematic review. J. Am. Acad. Dermatol. 82, 1346–1359 (2020).
pubmed: 31560977
pmcid: 31560977
Ehst, B. D., Minzer-Conzetti, K., Swerdlin, A. & Devere, T. S. Cutaneous manifestations of internal malignancy. Curr. Probl. Surg. 47, 384–445 (2010).
pubmed: 20363406
pmcid: 20363406
Le, S. T. et al. End stage scurvy in the developed world: a diagnostic conundrum but not to be mistaken for pyoderma gangrenosum. Int. Wound J. 16, 1024–1028 (2019).
pubmed: 31154667
pmcid: 31154667
Haag, C. K. et al. Pyoderma gangrenosum misdiagnosis resulting in amputation: a review. J. Trauma. Acute Care Surg. 86, 307–313 (2019).
pubmed: 30358767
pmcid: 30358767
El-Kehdy, J., Haneke, E. & Karam, P. G. Pyoderma gangrenosum: a misdiagnosis. J. Drugs Dermatol. 12, 228–230 (2013).
pubmed: 23377399
pmcid: 23377399
Conde Montero, E. et al. Factitious ulcer misdiagnosed as pyoderma gangrenosum. Wounds 28, 63–67 (2016).
pubmed: 26891139
pmcid: 26891139
Kumar, L. S., Shanmugasekar, C., Lakshmi, C. & Srinivas, C. R. Herpes misdiagnosed as pyoderma gangrenosum. Indian J. Sex. Transm. Dis. AIDS 30, 106–108 (2009).
pubmed: 21938131
pmcid: 21938131
Bradsher, R. W. Jr. The endemic mimic: blastomycosis an illness often misdiagnosed. Trans. Am. Clin. Climatol. Assoc. 125, 188–202 (2014).
pubmed: 25125734
pmcid: 25125734
Su, W. P., Davis, M. D., Weenig, R. H., Powell, F. C. & Perry, H. O. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int. J. Dermatol. 43, 790–800 (2004).
pubmed: 15533059
pmcid: 15533059
Le, S. T. et al. Peristomal pyoderma gangrenosum: an exceedingly rare and overdiagnosed entity? J. Am. Acad. Dermatol. https://doi.org/10.1016/j.jaad.2019.02.026 (2019).
doi: 10.1016/j.jaad.2019.02.026
pubmed: 30905803
pmcid: 30905803
Barton, V. R. et al. Peristomal ulcers misdiagnosed as pyoderma gangrenosum: a common error. J. Eur. Acad. Dermatol. Venereol. 34, e108–e110 (2020).
pubmed: 31667908
pmcid: 31667908
Jockenhofer, F., Wollina, U., Salva, K. A., Benson, S. & Dissemond, J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br. J. Dermatol. https://doi.org/10.1111/bjd.16401 (2018). This article presents a novel PG diagnostic model.
doi: 10.1111/bjd.16401
pubmed: 29388188
pmcid: 29388188
Maverakis, E. et al. New validated diagnostic criteria for pyoderma gangrenosum. J. Am. Acad. Dermatol. 80, e87–e88 (2019).
pubmed: 30557582
pmcid: 30557582
Craig, F. F. et al. UK Dermatology Clinical Trials Network’s STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials 13, 51 (2012).
pubmed: 22540770
pmcid: 22540770
Goodarzi, H. et al. Effective strategies for the management of pyoderma gangrenosum. Adv. Wound Care 1, 194–199 (2012).
Ahronowitz, I., Harp, J. & Shinkai, K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am. J. Clin. Dermatol. 13, 191–211 (2012).
pubmed: 22356259
pmcid: 22356259
Binus, A. M., Qureshi, A. A., Li, V. W. & Winterfield, L. S. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br. J. Dermatol. 165, 1244–1250 (2011). This retrospective analysis demonstrates that pathergy is present in only one-third of patients with PG.
pubmed: 21824126
pmcid: 21824126
Janowska, A. et al. PG-TIME: A practical approach to the clinical management of pyoderma gangrenosum. Dermatol. Ther. 33, e13412 (2020).
pubmed: 32291879
pmcid: 32291879
Woodland, J. et al. Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo. Ann. Rheum. Dis. 40, 355–359 (1981).
pubmed: 7020612
pmcid: 7020612
Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142, 257–265 (2012).
pubmed: 22062358
pmcid: 22062358
Landis, E. T., Taheri, A. & Jorizzo, J. L. Gulliver’s sign: a recognizable transition from inflammatory to healing stages of pyoderma gangrenosum. J. Dermatol. Treat. 26, 171–172 (2015).
Fonder, M. A., Cummins, D. L., Ehst, B. D., Anhalt, G. J. & Meyerle, J. H. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J. Burn. Wounds 5, e8 (2006).
Pomerantz, R. G., Husni, M. E., Mody, E. & Qureshi, A. A. Adalimumab for treatment of pyoderma gangrenosum. Br. J. Dermatol. 157, 1274–1275 (2007).
pubmed: 17916198
pmcid: 17916198
Zold, E., Nagy, A., Devenyi, K., Zeher, M. & Barta, Z. Successful use of adalimumab for treating fistulizing Crohn’s disease with pyoderma gangrenosum: two birds with one stone. World J. Gastroenterol. 15, 2293–2295 (2009).
pubmed: 19437575
pmcid: 19437575
Breedveld, F. C. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).
pubmed: 16385520
pmcid: 16385520
Bartelds, G. M. et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921–926 (2007).
pubmed: 17301106
pmcid: 17301106
Sivamani, R. K. et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin. Rev. Allergy Immunol. 44, 121–140 (2013).
pubmed: 22311162
pmcid: 22311162
Baltazar, D., Haag, C., Gupta, A. S., Marzano, A. M. & Ortega Loayza, A. G. A comprehensive review of local pharmacologic therapy for pyoderma gangrenosum. Wounds 31, 151–157 (2019).
pubmed: 31215868
pmcid: 31215868
Richter-Hintz, D., Schuppe, H. C., Homey, B., Lehmann, P. & Ruzicka, T. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J. Am. Acad. Dermatol. 42, 304–305 (2000).
pubmed: 10642695
pmcid: 10642695
Schuppe, H. C., Homey, B., Assmann, T., Martens, R. & Ruzicka, T. Topical tacrolimus for pyoderma gangrenosum. Lancet 351, 832 (1998).
pubmed: 9519983
pmcid: 9519983
Thomas, K. S. et al. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. J. Am. Acad. Dermatol. 75, 940–949 (2016).
pubmed: 27502313
pmcid: 27502313
Kochar, B. et al. Tofacitinib for the treatment of pyoderma gangrenosum. Clin. Gastroenterol. Hepatol. 17, 991–993 (2019).
pubmed: 30404036
pmcid: 30404036
Gregory, M. H., Ciorba, M. A., Deepak, P. & Christophi, G. P. Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab. Inflamm. Bowel Dis. 25, e87–e88 (2019).
pubmed: 30753456
pmcid: 30753456
Nasifoglu, S., Heinrich, B. & Welzel, J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br. J. Dermatol. 179, 504–505 (2018).
pubmed: 29451690
pmcid: 29451690
Moschella, S. L. Pyoderma gangrenosum. A patient successfully treated with intralesional injections of steroid. Arch. Dermatol. 95, 121–123 (1967).
pubmed: 6016300
pmcid: 6016300
Jennings, J. L. Pyoderma gangrenosum: successful treatment with intralesional steroids. J. Am. Acad. Dermatol. 9, 575–580 (1983).
pubmed: 6630619
pmcid: 6630619
Mrowietz, U. & Christophers, E. Clearing of pyoderma gangrenosum by intralesional cyclosporin A. Br. J. Dermatol. 125, 499 (1991).
pubmed: 1751361
pmcid: 1751361
He, Y., Maverakis, E., Ramirez-Maverakis, D. & Fitzmaurice, S. Combination therapy with intralesional triamcinolone and oral dapsone for management of palisaded neutrophilic and granulomatous dermatitis. Dermatol. Online J. 19, 17 (2013).
pubmed: 23473287
pmcid: 23473287
Ormerod, A. D. et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350, h2958 (2015). This is the largest randomized clinical trial ever conducted in PG.
pubmed: 26071094
pmcid: 26071094
Lu, J. D., Hobbs, M. M., Huang, W. W., Ortega-Loayza, A. G. & Alavi, A. Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review. Br. J. Dermatol. (2020).
Galun, E., Flugelman, M. Y. & Rachmilewitz, D. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am. J. Gastroenterol. 81, 988–989 (1986).
pubmed: 3766502
pmcid: 3766502
Shenefelt, P. D. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis 57, 315–319 (1996).
pubmed: 8726710
pmcid: 8726710
Hohenleutner, U., Mohr, V. D., Michel, S. & Landthaler, M. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum. Lancet 350, 1748 (1997).
pubmed: 9413469
pmcid: 9413469
Nousari, H. C., Lynch, W., Anhalt, G. J. & Petri, M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch. Dermatol. 134, 1509–1511 (1998).
pubmed: 9875186
pmcid: 9875186
Teitel, A. D. Treatment of pyoderma gangrenosum with methotrexate. Cutis 57, 326–328 (1996).
pubmed: 8726713
pmcid: 8726713
Toussi, A. et al. Successful management of anti-TNF-induced psoriasis despite continuation of therapy in a pyoderma gangrenosum patient. J. Drugs Dermatol. 19, 199–201 (2020).
pubmed: 32129973
pmcid: 32129973
Crawford, S. E., Sherman, R. & Favara, B. Pyoderma gangrenosum with response to cyclophosphamide therapy. J. Pediatr. 71, 255–258 (1967).
pubmed: 6029475
pmcid: 6029475
Roy, D. B., Conte, E. T. & Cohen, D. The treatment of pyoderma gangrenosum using etanercept. J. Am. Acad. Dermatol. 54, S128–S134 (2006).
pubmed: 16488326
pmcid: 16488326
Rogge, F. J., Pacifico, M. & Kang, N. Treatment of pyoderma gangrenosum with the anti-TNF alpha drug - Etanercept. J. Plast. Reconstr. Aesthet. Surg. 61, 431–433 (2008).
pubmed: 18358433
pmcid: 18358433
Pastor, N. et al. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin. Exp. Dermatol. 31, 152–153 (2006).
pubmed: 16309525
pmcid: 16309525
Goldenberg, G. & Jorizzo, J. L. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J. Dermatol. Treat. 16, 347–349 (2005).
Disla, E., Quayum, B., Cuppari, G. G. & Pancorbo, R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin. Rheumatol. 10, 50–52 (2004).
Charles, C. A., Leon, A., Banta, M. R. & Kirsner, R. S. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int. J. Dermatol. 46, 1095–1099 (2007).
pubmed: 17910724
pmcid: 17910724
Hurabielle, C. et al. Certolizumab pegol - a new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease. J. Dermatol. Treat. 27, 67–69 (2016).
Goldminz, A. M., Botto, N. C. & Gottlieb, A. B. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J. Am. Acad. Dermatol. 67, e237–e238 (2012).
pubmed: 23062936
pmcid: 23062936
John, J. M. & Sinclair, R. D. Tildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: killing two birds with one stone. Australas. J. Dermatol. https://doi.org/10.1111/ajd.13196 (2019).
doi: 10.1111/ajd.13196
pubmed: 31729012
pmcid: 31729012
Moreno Garcia, M., Madrid Gonzalez, M. & Prada Lobato, J. M. Secukinumab for pyoderma gangrenosum: a case report. Med. Clin. 152, 246 (2019).
Brenner, M., Ruzicka, T., Plewig, G., Thomas, P. & Herzer, P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol. 161, 1199–1201 (2009).
pubmed: 19673875
Kolios, A. G. et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br. J. Dermatol. 173, 1216–1223 (2015).
pubmed: 26471257
pmcid: 26471257
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01882504 (2016).
Lee, W. S., Choi, Y. J. & Yoo, W. H. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J. Eur. Acad. Dermatol. Venereol. 31, e75–e77 (2017).
pubmed: 27325564
pmcid: 27325564
Cummins, D. L., Anhalt, G. J., Monahan, T. & Meyerle, J. H. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br. J. Dermatol. 157, 1235–1239 (2007).
pubmed: 17916196
pmcid: 17916196
Hagman, J. H., Carrozzo, A. M., Campione, E., Romanelli, P. & Chimenti, S. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J. Dermatol. Treat. 12, 19–22 (2001).
Kreuter, A., Reich-Schupke, S., Stucker, M., Altmeyer, P. & Gambichler, T. Intravenous immunoglobulin for pyoderma gangrenosum. Br. J. Dermatol. 158, 856–857 (2008).
pubmed: 18241257
pmcid: 18241257
Laird, M. E. et al. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. JAAD Case Rep. 3, 228–229 (2017).
pubmed: 28443317
pmcid: 28443317
Beam, J. W. Wound cleansing: water or saline? J. Athl. Train. 41, 196–197 (2006).
Nguyen, L. Q. & Weiner, J. Treatment of pyoderma gangrenosum with benzoyl peroxide. Cutis 19, 842–844 (1977).
pubmed: 872625
pmcid: 872625
Wilkins, R. G. & Unverdorben, M. Wound cleaning and wound healing: a concise review. Adv. Skin. Wound Care 26, 160–163 (2013).
pubmed: 23507692
pmcid: 23507692
Mahoney, E. & Kelly, C. B. in Orthotics and Prosthetics in Rehabilitation (Elsevier, 2013).
Powers, J. G., Higham, C., Broussard, K. & Phillips, T. J. Wound healing and treating wounds: chronic wound care and management. J. Am. Acad. Dermatol. 74, 607–625 (2016).
pubmed: 26979353
pmcid: 26979353
Lipsky, B. A. & Hoey, C. Topical antimicrobial therapy for treating chronic wounds. Clin. Infect. Dis. 49, 1541–1549 (2009).
pubmed: 19842981
pmcid: 19842981
Lobmann, R., Zemlin, C., Motzkau, M., Reschke, K. & Lehnert, H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J. Diabetes Complicat. 20, 329–335 (2006).
pubmed: 16949521
pmcid: 16949521
Maida, V. & Corban, J. Topical medical cannabis: a new treatment for wound pain-three cases of pyoderma gangrenosum. J. Pain Symptom Manage. 54, 732–736 (2017).
pubmed: 28818631
pmcid: 28818631
Schwartz, P. M., Barnett, S. K., Atillasoy, E. S. & Milstone, L. M. Methotrexate induces differentiation of human keratinocytes. Proc. Natl Acad. Sci. USA 89, 594–598 (1992).
pubmed: 1731329
pmcid: 1731329
Long, C. C., Jessop, J., Young, M. & Holt, P. J. Minimizing the risk of post-operative pyoderma gangrenosum. Br. J. Dermatol. 127, 45–48 (1992).
pubmed: 1637694
pmcid: 1637694
Zuo, K. J., Fung, E., Tredget, E. E. & Lin, A. N. A systematic review of post-surgical pyoderma gangrenosum: identification of risk factors and proposed management strategy. J. Plast. Reconstr. Aesthet. Surg. 68, 295–303 (2015).
pubmed: 25589459
pmcid: 25589459
Steele, R. B. et al. Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment. Br. J. Dermatol. 174, 77–87 (2016).
pubmed: 26474193
pmcid: 26474193
Sanchez, I. M. et al. Clinical features of neutrophilic dermatosis variants resembling necrotizing fasciitis. JAMA Dermatol. 155, 79–84 (2019).
pubmed: 30383110
pmcid: 30383110
Crittenden, S. C., Gilbert, J. E. & Callen, J. P. Hydroxyurea-induced leg ulceration in a patient with a homozygous MTHFR polymorphism misdiagnosed as pyoderma gangrenosum. JAMA Dermatol. 150, 780–781 (2014).
pubmed: 24599173
pmcid: 24599173
Delgado-Jimenez, Y. et al. Extranodal NK/T-cell lymphoma nasal type mimicking pyoderma gangrenosum. Acta Derm. Venereol. 87, 176–177 (2007).
pubmed: 17340032
pmcid: 17340032
Ho, K. K., Browne, A., Fitzgibbons, J., Carney, D. & Powell, F. C. Mycosis fungoides bullosa simulating pyoderma gangrenosum. Br. J. Dermatol. 142, 124–127 (2000).
pubmed: 10651707
pmcid: 10651707
Jasch, K. C., Hermes, B., Scheller, U. & Harth, W. Pyoderma gangrenosum-like primary cutaneous cryptococcosis. Acta Derm. Venereol. 88, 76–77 (2008).
pubmed: 18176763
pmcid: 18176763
Kerr, O. A., Bong, C., Wallis, C. & Tidman, M. J. Primary cutaneous mucormycosis masquerading as pyoderma gangrenosum. Br. J. Dermatol. 150, 1212–1213 (2004).
pubmed: 15214915
pmcid: 15214915
Kikuchi, N. et al. Cutaneous cryptococcosis mimicking pyoderma gangrenosum: a report of four cases. Acta Derm. Venereol. 96, 116–117 (2016).
pubmed: 26039271
pmcid: 26039271
Murray, P. R. et al. Pyoderma gangrenosum-like ulcer in a patient with X-linked agammaglobulinemia: identification of Helicobacter bilis by mass spectrometry analysis. Arch. Dermatol. 146, 523–526 (2010).
pubmed: 20479300
pmcid: 20479300
New, D., Eaton, P., Knable, A. & Callen, J. P. The use of B vitamins for cutaneous ulcerations mimicking pyoderma gangrenosum in patients with MTHFR polymorphism. Arch. Dermatol. 147, 450–453 (2011).
pubmed: 21482894
pmcid: 21482894
Eisendle, K., Thuile, T., Deluca, J. & Pichler, M. Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and skin grafting, including xenografts: personal experience and comprehensive review on 161 cases. Adv. Wound Care 9, 405–425 (2020).
Xia, F. D. et al. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-A retrospective analysis. J. Am. Acad. Dermatol. 78, 310–314.e311 (2018). This article establishes the incidence of PG recurrence following surgical procedures.
pubmed: 28947285
pmcid: 28947285
Haag, C. K. et al. Perioperative management of pyoderma gangrenosum. J. Am. Acad. Dermatol. https://doi.org/10.1016/j.jaad.2020.01.002 (2020).
doi: 10.1016/j.jaad.2020.01.002
pubmed: 31927079
pmcid: 31927079
Gerard, A. J., Feldman, S. R. & Strowd, L. Quality of life of patients with pyoderma gangrenosum and hidradenitis suppurativa. J. Cutan. Med. Surg. 19, 391–396 (2015).
pubmed: 25775617
pmcid: 25775617
Augustin, M. et al. Validity and feasibility of the wound-QoL questionnaire on health-related quality of life in chronic wounds. Wound Repair. Regen. 25, 852–857 (2017).
pubmed: 29080332
pmcid: 29080332
Ighani, A. et al. Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. Br. J. Dermatol. 180, 672–673 (2019).
pubmed: 30362501
pmcid: 30362501
Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S. & Finlay, A. Y. The dermatology life quality index 1994–2007: a comprehensive review of validation data and clinical results. Br. J. Dermatol. 159, 997–1035 (2008).
pubmed: 18795920
pmcid: 18795920
Dyer, M. T. D., Goldsmith, K. A., Sharples, L. S. & Buxton, M. J. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual. Life Outcomes 8, 13 (2010).
pubmed: 20109189
pmcid: 20109189
Huppertz-Hauss, G. et al. Comparison of the multiattribute utility instruments EQ-5D and SF-6D in a Europe-wide population-based cohort of patients with inflammatory bowel disease 10 years after diagnosis. Gastroenterol. Res. Pract. 2016, 5023973 (2016).
pubmed: 27630711
pmcid: 27630711
Beiteke, U., Bigge, S., Reichenberger, C. & Gralow, I. Pain and pain management in dermatology. J. Dtsch. Dermatol. Ges. 13, 967–987 (2015).
pubmed: 26408457
pmcid: 26408457
Wu, X. R. & Shen, B. Diagnosis and management of parastomal pyoderma gangrenosum. Gastroenterol. Rep. 1, 1–8 (2013).
Karimkhani, C. et al. Global skin disease morbidity and mortality: an update from the global burden of disease study 2013. JAMA Dermatol. 153, 406–412 (2017).
pubmed: 28249066
pmcid: 28249066
Thomas, K. S. et al. A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease. Programme Grants for Applied Research https://doi.org/10.3310/pgfar04180 (2016).
doi: 10.3310/pgfar04180
Chimento, S. et al. Evaluation of osteopontin expression in chronic wounds: a potential prognostic and therapeutic biomarker. J. Wound Care 26, S4–S8 (2017).
pubmed: 28880752
pmcid: 28880752
Zhang, H., Zeng, Z., Mukherjee, A. & Shen, B. Molecular diagnosis and classification of inflammatory bowel disease. Expert. Rev. Mol. Diagn. 18, 867–886 (2018).
pubmed: 30152711
pmcid: 30152711
Nakken, B. et al. Biomarkers for rheumatoid arthritis: from molecular processes to diagnostic applications-current concepts and future perspectives. Immunol. Lett. 189, 13–18 (2017).
pubmed: 28526580
pmcid: 28526580
Sadik, C. D., Miyabe, Y., Sezin, T. & Luster, A. D. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. Semin. Immunol. 37, 21–29 (2018).
pubmed: 29602515
pmcid: 29602515
Woodruff, T. M., Nandakumar, K. S. & Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48, 1631–1642 (2011).
pubmed: 21549429
pmcid: 21549429
Feagan, B. G. et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389, 1699–1709 (2017).
pubmed: 28411872
pmcid: 28411872
Duchatelet, S. et al. First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome. Br. J. Dermatol. 173, 610–612 (2015).
pubmed: 25601011
pmcid: 25601011
Marzano, A. V. et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 149, 762–764 (2013).
pubmed: 23571383
pmcid: 23571383
Chamot, A. M. et al. [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases]. Rev. Rhum. Mal. Osteoartic. 54, 187–196 (1987).
pubmed: 2954204
pmcid: 2954204
Hurtado-Nedelec, M. et al. Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes. J. Rheumatol. 37, 401–409 (2010).
pubmed: 20032092
pmcid: 20032092
Perry, H. O. & Winkelmann, R. K. Bullous pyoderma gangrenosum and leukemia. Arch. Dermatol. 106, 901–905 (1972).
pubmed: 4508849
pmcid: 4508849
Wilson-Jones, E. & Winkelmann, R. K. Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. J. Am. Acad. Dermatol. 18, 511–521 (1988).
pubmed: 3351014
pmcid: 3351014
Powell, F. C., Su, W. P. & Perry, H. O. Pyoderma gangrenosum: classification and management. J. Am. Acad. Dermatol. 34, 395–409 (1996).
pubmed: 8609250
pmcid: 8609250
Ho, K. K.-L., Otridge, B. W., Vandenberg, E. & Powell, F. C. Pyoderma gangrenosum, polycythemia rubra vera, and the development of leukemia. J. Am. Acad. Dermatol. 27, 804–808 (1992).
pubmed: 1469131
pmcid: 1469131
Callen, J. P. & Woo, T. Y. Vesiculopustular eruption in a patient with ulcerative colitis. Pyoderma gangrenosum. Arch. Dermatol. 121, 399–400 (1985).
pubmed: 3977364
pmcid: 3977364
Quimby, S. R., Gibson, L. E. & Winkelmann, R. K. Superficial granulomatous pyoderma: clinicopathologic spectrum. Mayo Clin. Proc. 64, 37–43 (1989).
pubmed: 2911214
pmcid: 2911214
Ahmadi, S. & Powell, F. C. Pyoderma gangrenosum: uncommon presentations. Clin. Dermatol. 23, 612–620 (2005).
pubmed: 16325070
pmcid: 16325070
Brunsting, L. A., Goeckerman, W. H. & O’Leary, P. A. Pyoderma (echthyma) gangrenosum. Arch. Derm. Syphilol. 22, 655–680 (1930).
O’Loughlin, S. & Perry, H. O. A diffuse pustular eruption associated with ulcerative colitis. Arch. Dermatol. 114, 1061–1064 (1978).
pubmed: 686728
pmcid: 686728
Hughes, A. P., Jackson, J. M. & Callen, J. P. Clinical features and treatment of peristomal pyoderma grangrenosum. J. Am. Med. Assoc. 284, 1546–1548 (2000).
Tolkachjov, S. N. et al. Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. J. Am. Acad. Dermatol. 73, 615–622 (2015).
pubmed: 26209218
pmcid: 26209218
Wang, J. Y. et al. Gangrenosum: a review. Am. J. Clin. Dermatol. 19, 67–77 (2018).
pubmed: 28624960
pmcid: 28624960
Galaria, N. A., Junkins-Hopkins, J. M., Kligman, D. & James, W. D. Neutrophilic dermatosis of the dorsal hands: pustular vasculitis revisited. J. Am. Acad. Dermatol. 43, 870–874 (2000).
pubmed: 11050599
pmcid: 11050599
Walling, H. W., Snipes, C. J., Gerami, P. & Piette, W. W. The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum. Arch. Dermatol. 142, 57–63 (2006).
pubmed: 16415387
pmcid: 16415387